创伤护理生技药品市场规模、份额和成长分析（按产品、伤口类型、最终用户和地区）- 产业预测 2025-2032

预计 2023 年全球创伤护理生技药品市场规模将达到 17.9 亿美元，并从 2024 年的 18.8 亿美元增长到 2032 年的 28.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.2%。

受医疗技术进步和创新治疗方案需求不断增长的推动，全球创伤护理生技药品市场呈现强劲增长势头。这些产品含有生长因子和干细胞等生物材料，在医疗保健领域越来越受欢迎，可有效治疗慢性伤口、糖尿病足溃疡和烧伤。造成这种情况的原因包括慢性病发病率上升、老龄人口增加以及伤口癒合时间变慢。个人化医疗和先进医疗保健的趋势以及尽量减少住院时间和医疗费用的努力进一步推动了这一趋势。然而，高成本、严格的法规以及医疗专业人员的认识有限等挑战可能会阻碍市场扩张，并对生技药品在创伤护理中的广泛应用造成障碍。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 案例研究

创伤护理生技药品市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• 生物皮肤替代品
  • 人类供体组织衍生产品
  • 无细胞动物产品
  • 生物合成产品
• 外用药物

创伤护理生技药品市场规模（按伤口类型和复合年增长率） (2025-2032)

• 市场概况
• 溃疡
  • 糖尿病足溃疡
  • 静脉溃疡
  • 压疮
  • 其他溃疡
• 外科性创伤与创伤伤口
• 烧伤

创伤护理生技药品市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概况
• 医院
• 门诊手术中心
• 烧烫伤中心和伤口护理诊所

创伤护理生技药品市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分析市场份额
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Smith & Nephew（United Kingdom）
• Integra LifeSciences（United States）
• Organogenesis Holdings Inc.（United States）
• MiMedx Group, Inc.（United States）
• Osiris Therapeutics, Inc.（United States）
• Aroa Biosurgery（New Zealand）
• Avita Medical（Australia）
• Derma Sciences, Inc.（United States）
• Alliqua BioMedical, Inc.（United States）
• Amnio Technology, LLC（United States）
• Tissue Regenix Group plc（United Kingdom）
• CollPlant Biotechnologies Ltd.（Israel）
• RenovaCare, Inc.（United States）
• PolarityTE, Inc.（United States）
• Cytori Therapeutics, Inc.（United States）
• Histogenics Corporation（United States）
• Vericel Corporation（United States）
• RepliCel Life Sciences Inc.（Canada）

结论和建议

Global Wound Care Biologics Market size was valued at USD 1.79 billion in 2023 and is poised to grow from USD 1.88 billion in 2024 to USD 2.82 billion by 2032, growing at a CAGR of 5.2% during the forecast period (2025-2032).

The global wound care biologics market is on a robust growth trajectory, fueled by advancements in healthcare technology and increasing demand for innovative healing solutions. Comprising biological substances like growth factors and stem cells, these products effectively address chronic wounds, diabetic foot ulcers, and burns, thereby gaining traction in healthcare settings. Contributing factors include the rising incidence of chronic ailments and a growing elderly demographic vulnerable to slow-healing wounds. The movement towards personalized medicine and advanced therapies, as well as efforts to minimize hospital stays and healthcare costs, further support this trend. However, challenges such as high costs, stringent regulations, and limited awareness among healthcare professionals may inhibit market expansion, creating hurdles for widespread adoption of wound care biologics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Wound Care Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Wound Care Biologics Market Segments Analysis

Global Wound Care Biologics Market is segmented by Product, Wound Type, End User and region. Based on Product, the market is segmented into Biological Skin Substitutes and Topical Agents. Based on Wound Type, the market is segmented into Ulcers, Surgical & Traumatic Wounds and Burns. Based on End User, the market is segmented into Hospitals, Ambulatory Surgery Centers and Burn Care Centers & Wound Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Wound Care Biologics Market

The global wound care biologics market is significantly propelled by the rising prevalence of chronic wounds, particularly diabetic foot ulcers and pressure ulcers. These conditions create a growing demand for innovative treatment solutions. Biologic wound care products provide exceptional therapeutic alternatives that enhance the healing process for difficult cases, making them increasingly vital in modern wound management. As healthcare professionals seek effective ways to address these complex ailments, the need for advanced biologics becomes more pronounced, driving the market's expansion. This trend underscores the critical role of biologics in improving patient outcomes in wound care settings.

Restraints in the Global Wound Care Biologics Market

The Global Wound Care Biologics market faces significant restraints due to the stringent regulatory approval processes associated with biologic wound care products. These rigorous protocols can prolong the time it takes for new products to enter the market, which not only hampers timely access for healthcare providers and patients but also escalates the overall development costs for manufacturers. As companies navigate through comprehensive testing and compliance requirements, the financial burden and extended timelines can deter innovation and the introduction of potentially beneficial solutions, ultimately impacting the growth and dynamics of the market.

Market Trends of the Global Wound Care Biologics Market

The Global Wound Care Biologics market is experiencing a significant trend towards personalized medicine, reflecting a broader healthcare shift in which treatments are customized to meet individual patient needs and specific wound characteristics. This tailored approach enhances treatment efficacy, as wound care biologics-such as growth factors, collagen-based products, and stem cell therapies-offer targeted healing solutions that address unique patient profiles. The rising prevalence of chronic wounds and advancements in biologic technologies further drive this market trend, pushing for innovations that integrate personalized strategies into standard wound care practices, thus improving patient outcomes and fostering competitive differentiation among market players.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Wound Care Biologics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Biological Skin Substitutes
  • Human Donor Tissue-derived Products
  • Acellular Animal-derived Products
  • Biosynthetic Products
• Topical Agents

Global Wound Care Biologics Market Size by Wound Type & CAGR (2025-2032)

• Market Overview
• Ulcers
  • Diabetic Foot Ulcers
  • Venous Ulcers
  • Pressure Ulcers
  • Other Ulcers
• Surgical & Traumatic Wounds
• Burns

Global Wound Care Biologics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Ambulatory Surgery Centers
• Burn Care Centers & Wound Clinics

Global Wound Care Biologics Market Size & CAGR (2025-2032)

• North America (Product, Wound Type, End User)
  • US
  • Canada
• Europe (Product, Wound Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Wound Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Wound Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Wound Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Smith & Nephew (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integra LifeSciences (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Organogenesis Holdings Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MiMedx Group, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Osiris Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aroa Biosurgery (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avita Medical (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Derma Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alliqua BioMedical, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amnio Technology, LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tissue Regenix Group plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CollPlant Biotechnologies Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RenovaCare, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PolarityTE, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cytori Therapeutics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Histogenics Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vericel Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RepliCel Life Sciences Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations